Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VAMSI KOTA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1790902393
CMS profile
172817
Location
AUGUSTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$11,661.76

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $6,081.80 5
NOVARTIS PHARMACEUTICALS CORPORATION $5,556.07 13
Celgene Corporation $23.89 1

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VAMSI KOTA

NPI 1790902393 · CMS profile ID 172817

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

AUGUSTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790902393?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VAMSI KOTA, NPI 1790902393, CMS profile ID 172817. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790902393?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). VAMSI KOTA, NPI 1790902393, CMS profile ID 172817. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790902393?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
VAMSI KOTA, NPI 1790902393, CMS profile ID 172817, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790902393?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $11,661.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $22.6312/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718143 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $89.2212/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709077813 CMS
PFIZER INC. $4,050.0010/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673802039 CMS
Novartis Pharmaceuticals Corporation $1,965.0010/18/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718145 CMS
Novartis Pharmaceuticals Corporation $30.8310/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718141 CMS
Novartis Pharmaceuticals Corporation $22.8210/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718157 CMS
Novartis Pharmaceuticals Corporation $40.5310/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718159 CMS
PFIZER INC. $369.0009/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673800541 CMS
PFIZER INC. $392.8009/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673818069 CMS
Novartis Pharmaceuticals Corporation $655.0008/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718149 CMS
Novartis Pharmaceuticals Corporation $2,620.0007/18/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718151 CMS
Novartis Pharmaceuticals Corporation $13.4206/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718139 CMS
PFIZER INC. $940.0006/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673804735 CMS
Novartis Pharmaceuticals Corporation $20.8105/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718147 CMS
Novartis Pharmaceuticals Corporation $16.0403/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718137 CMS
Novartis Pharmaceuticals Corporation $53.0302/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718153 CMS
Novartis Pharmaceuticals Corporation $6.7402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659718155 CMS
Celgene Corporation $23.8902/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672733891 CMS
PFIZER INC. $330.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673819543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,661.76 19
PY2020 $18,136.16 15
PY2021 $11,422.95 11
PY2022 $10,850.77 14
PY2023 $17,073.30 19
PY2024 $8,407.15 7
PY2025 $13,747.64 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $132,060.46 16
PY2024 Recipient $4,666.04 2
PY2024 Principal investigator $39,767.00 22
PY2023 Recipient $11,715.50 3
PY2023 Principal investigator $52,606.84 7
PY2022 Recipient $9,994.00 10
PY2022 Principal investigator $107,035.90 12
PY2021 Recipient $8,130.00 4
PY2021 Principal investigator $310,967.41 28
PY2020 Recipient $17,342.00 13
PY2020 Principal investigator $404,017.84 37
PY2019 Principal investigator $397,422.88 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Celgene Corporation $632.00 12/02/2021 Non-covered Recipient Entity
Georgia Health Sciences University
A Phase 3b, Multicenter, Single-Arm, Open-Label Ef No dispute reported 06/30/2026 807117507
Recipient PFIZER INC. $3,200.00 11/26/2021 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832529369
Recipient PFIZER INC. $1,400.00 11/16/2021 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832529359
Principal investigator 1 Astellas Pharma Global Development $4,800.00 11/04/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
Randomized Trial of Gilteritinib vs Midostaurin in FL T3 Mutated Acute Myeloid Leukemia No dispute reported 06/30/2026 801081159
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,170.50 11/02/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 816773085
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $633.00 09/21/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 816760655
Principal investigator 1 Incyte Corporation $57.30 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144825
Principal investigator 1 Incyte Corporation $80.20 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144827
Principal investigator 1 Incyte Corporation $45.60 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144829
Principal investigator 1 Incyte Corporation $11.70 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144831
Principal investigator 1 Incyte Corporation $232.98 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144833
Principal investigator 1 Incyte Corporation $143.25 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144835
Principal investigator 1 Incyte Corporation $100.25 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144837
Principal investigator 1 Incyte Corporation $76.00 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144839
Principal investigator 1 Incyte Corporation $423.60 09/09/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144841
Recipient PFIZER INC. $3,200.00 09/02/2021 Covered Recipient Physician BOSUTINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832584975
Principal investigator 1 PFIZER INC. $14,888.00 08/26/2021 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMTUZUMAB OZOGAMICIN MYLOTARG TRADEMARKER AS A SINGLEAGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33POSITIVE ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 832709663
Recipient PFIZER INC. $330.00 08/03/2021 Covered Recipient Physician AML CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832559877
Principal investigator 1 Incyte Corporation $147,857.00 06/28/2021 Non-covered Recipient Entity
Augusta University Research Institute
Not supplied No dispute reported 06/30/2026 831148673
Principal investigator 1 Astellas Pharma Global Development $5,000.00 06/10/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
Randomized Trial of Gilteritinib vs Midostaurin in FL T3 Mutated Acute Myeloid Leukemia No dispute reported 06/30/2026 801080353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,625.00 05/24/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 816727353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $38,542.00 05/17/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 816724500
Principal investigator 1 Incyte Corporation $20.91 05/10/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144785
Principal investigator 1 Incyte Corporation $63.82 05/10/2021 Non-covered Recipient Entity
GEORGIA CANCER CENTER
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 831144787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,492.80 04/27/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 816716969
Principal investigator 1 PFIZER INC. $4,417.50 03/16/2021 Non-covered Recipient Entity
Augusta University Research Institute Inc
A SINGLE ARM OPENLABEL PHASE 4 STUDY EVALUATING QT INTERVAL PHARMACOKINETICS AND SAFETY OF GEMTUZUMAB OZOGAMICIN MYLOTARG TRADEMARKER AS A SINGLEAGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33POSITIVE ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 832812295
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56,795.75 02/16/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) No dispute reported 06/30/2026 816689101
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,548.25 02/02/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 816686343
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $860.00 02/02/2021 Non-covered Recipient Entity
WCG IRB
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 816686353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 02/02/2021 Non-covered Recipient Entity
WCG IRB
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 816686363
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 02/02/2021 Non-covered Recipient Entity
WCG IRB
VEDOLIZUMAB IN THE PROPHYLAXIS OF INTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PARTICIPANTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL (ALLO-HSCT) TRANSPLANTATION No dispute reported 06/30/2026 816686373
Principal investigator 1 Amgen Inc. $7,950.00 01/18/2021 Non-covered Recipient Entity
AUGUSTA UNIVERSITY RESEARCH INSTITU
Not supplied No dispute reported 06/30/2026 830975591